UBS on Wednesday reported a $1.1bn net profit for the three months to the end of June, beating analyst forecasts as it steps up its integration of former rival Credit Suisse.

“We are well positioned to meet our financial targets and return to the levels of profitability we delivered before being asked to step in and stabilise Credit Suisse,” said chief executive Sergio Ermotti. “We are now entering the next phase of our integration.”

Analysts in a Bloomberg poll had forecast the Swiss lender to report $520.8mn in net profit for the second quarter.

Almost 18 months after its rescue of Credit Suisse, UBS is locked in a public spat with Swiss authorities over increased capital requirements the government has proposed for the enlarged bank.

Analysts have forecast that the rule change could lead to between $15bn and $25bn of additional capital for UBS.

The proposal, one of several made by Swiss finance minister Karin Keller-Sutter in April and designed to strengthen the country’s too-big-to-fail regulations, tempered a rally in UBS shares.

Nevertheless, the stock remains up almost 50 per cent since UBS agreed to buy its rival in March 2023.

The quarterly results come just months after UBS split the leadership of its wealth management business, a key profit engine, between Iqbal Khan and Rob Karofsky. The pair are seen as potential successors to Ermotti.

.

You May Also Like

This little-noticed update to Medicaid rules could burden seniors with thousands in medical debt

Seniors relying on Medicare escaped Trump’s big budget law mostly unscathed. Those…

Stocks and bonds haven’t moved together like this in three decades – and that’s putting portfolios at risk, says State Street 

A so-called balanced portfolio is anything but given the correlation of stock…

Gen Z is willing to accept lower pay in exchange for better work-life balance

Gen Z’s need for “stability, sustainability and safety” in the workplace is…

Eisai stock slumps after Alzheimer’s drug fails to get approval in Europe

Eisai shares fell sharply after its Alzheimer’s drug failed to secure marketing…